| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
SIRT5 40 nM (Ki)
The specific biological targets of Et-29 have not been extensively documented in the available literature. As a research compound, it may target specific proteins, enzymes, or receptors depending on its chemical structure and design. Further studies are needed to elucidate the precise molecular targets and mechanisms of action of Et-29. |
|---|---|
| ln Vitro |
In vitro activity of Et-29 has not been extensively documented in the available literature. As a research compound, its activity would depend on the specific biological target and assay conditions. Studies in appropriate cellular systems would be needed to evaluate its potency, efficacy, and mechanism of action. The compound is typically used in laboratory research settings.
|
| ln Vivo |
In vivo studies for Et-29 have not been extensively documented in the available literature. As a research compound, its potential for in vivo applications would depend on its pharmacokinetic properties and therapeutic potential. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile.
|
| Enzyme Assay |
The experimental protocols for Et-29 would depend on the specific biological target and application. Typical assays for small molecule research compounds include enzyme inhibition assays, receptor binding assays, and cellular activity assays. The compound would be tested at various concentrations to determine its potency and efficacy. Standard laboratory techniques such as spectrophotometry, fluorescence, or mass spectrometry would be used to measure activity.
|
| Cell Assay |
For cellular studies, appropriate cell lines would be cultured in appropriate media and treated with Et-29 at various concentrations. Cellular responses would be assessed depending on the specific target and application, including cell viability, proliferation, apoptosis, or specific signaling pathway activation. Standard assays such as MTT, Western blot, ELISA, or flow cytometry would be used to evaluate cellular effects.
|
| Animal Protocol |
For in vivo studies, appropriate animal models would be used to evaluate Et-29. The compound would be administered via appropriate routes at various doses. Pharmacokinetic parameters including half-life, clearance, and tissue distribution would be determined. Efficacy would be evaluated by measuring disease biomarkers, survival, or histological analysis. However, detailed in vivo protocols for Et-29 have not been extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Et-29 have not been fully characterized in the available literature. As a research compound, its ADME properties would need to be determined through appropriate studies. The compound is typically stored according to manufacturer recommendations. Comprehensive PK studies are needed to fully understand its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Et-29 is a research compound intended for laboratory use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound. The compound should be stored according to manufacturer recommendations to maintain stability.
|
| References | |
| Additional Infomation |
Et-29 is a research compound used in chemical biology and drug discovery research. Detailed information about its structure, targets, and biological activity is limited in the publicly available literature. The compound is for research use only and has not been approved for clinical applications.
|
| Molecular Formula |
C34H46N6O6S
|
|---|---|
| Molecular Weight |
666.83
|
| Exact Mass |
666.319
|
| CAS # |
2166487-23-4
|
| PubChem CID |
162641741
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
47
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(C1=CNC2=CC=CC=C12)[C@@H](C(=O)NC(C)C)NC(=O)[C@H](CCCCNC(=S)NCCC(=O)OCC)NC(=O)OCC1C=CC=CC=1
|
| InChi Key |
DCENHWUVADDCEN-VMPREFPWSA-N
|
| InChi Code |
InChI=1S/C34H46N6O6S/c1-4-45-30(41)17-19-36-33(47)35-18-11-10-16-28(40-34(44)46-22-24-12-6-5-7-13-24)31(42)39-29(32(43)38-23(2)3)20-25-21-37-27-15-9-8-14-26(25)27/h5-9,12-15,21,23,28-29,37H,4,10-11,16-20,22H2,1-3H3,(H,38,43)(H,39,42)(H,40,44)(H2,35,36,47)/t28-,29-/m0/s1
|
| Chemical Name |
ethyl 3-[[(5S)-6-[[(2S)-3-(1H-indol-3-yl)-1-oxo-1-(propan-2-ylamino)propan-2-yl]amino]-6-oxo-5-(phenylmethoxycarbonylamino)hexyl]carbamothioylamino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (149.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.75 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4996 mL | 7.4982 mL | 14.9963 mL | |
| 5 mM | 0.2999 mL | 1.4996 mL | 2.9993 mL | |
| 10 mM | 0.1500 mL | 0.7498 mL | 1.4996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
